IQVIA Holdings Announces $2 Billion Senior Notes Offering
TipRanks (Wed, 9-Sep 6:20 PM ET)
IQVIA prices $2B of senior notes due 2034
Seeking Alpha News (Wed, 9-Sep 5:23 PM ET)
IQVIA Announces Pricing of Senior Notes
Business Wire (Wed, 9-Sep 5:13 PM ET)
IQVIA backs real world pegcetacoplan study in rare kidney disease
TipRanks (Wed, 9-Sep 12:31 PM ET)
IQVIA Announces Offering of Senior Notes
Business Wire (Wed, 9-Sep 8:15 AM ET)
Business Wire (Thu, 3-Sep 4:15 PM ET)
Business Wire (Thu, 27-Aug 4:15 PM ET)
Business Wire (Thu, 20-Aug 4:15 PM ET)
IQVIA Ranked No. 1 Pharmaceutical Technology Provider by Everest Group
Business Wire (Mon, 17-Aug 4:15 PM ET)
Market Chameleon (Wed, 5-Aug 5:50 AM ET)
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.
Iqvia Holdings trades on the NYSE stock market under the symbol IQV.
As of September 11, 2026, IQV stock price climbed to $261.77 with 1,340,480 million shares trading.
IQV has a beta of 0.89, meaning it tends to be less sensitive to market movements. IQV has a correlation of 0.06 to the broad based SPY ETF.
IQV has a market cap of $43.09 billion. This is considered a Large Cap stock.
Last quarter Iqvia Holdings reported $4 billion in Revenue and $3.15 earnings per share. This beat revenue expectation by $63 million and exceeded earnings estimates by $.18.
In the last 3 years, IQV traded as high as $271.80 and as low as $134.65.
The top ETF exchange traded funds that IQV belongs to (by Net Assets): VTI, VOO, VO, SPY, VTV.
IQV has outperformed the market in the last year with a price return of +42.4% while the SPY ETF gained +18.3%. IQV has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +43.7% and -0.2%, respectively, while the SPY returned +5.6% and -0.9%, respectively.
IQV support price is $252.17 and resistance is $262.43 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IQV shares will trade within this expected range on the day.
